Evaluation of Injection Frequency and Visual Acuity Outcomes for Ranibizumab Monotherapy in Exudative Age-related Macular Degeneration

Ophthalmology

Volumn 116, Issue 9, 2009, Pages 1740-1747

  Dadgostar, Hajir ^a   Ventura, Alexandre A C M ^a   Chung, Jeffrey Y ^a   Sharma, Sumit ^a   Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HUMAN; INJECTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; VISUAL ACUITY;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; EXUDATES AND TRANSUDATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 69249213449     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.05.033     Document Type: Article

References (13)

1. Bressler N.M. Age-related macular degeneration is the leading cause of blindness. JAMA 291 (2004) 1900-1901
2. Dadgostar H., and Waheed N. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye 22 (2008) 761-767
3. Brown D.M., Kaiser P.K., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
4. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
5. Fung A.E., Lalwani G.A., Rosenfeld P.J., et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143 (2007) 566-583
6. Holladay J.T. Visual acuity measurements. J Cataract Refract Surg 30 (2004) 287-290
7. Fung A.E., Rosenfeld P.J., and Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol 90 (2006) 1344-1349
8. Wu L., Martinez-Castellanos M.A., Quiroz-Mercado H., et al., Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246 (2007) 81-87
9. Freeman W.R., and Falkenstein I. Avastin and new treatments for AMD: where are we?. Retina 26 (2006) 853-858
10. Raftery J., Clegg A., Jones J., et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 91 (2007) 1244-1246
11. Regillo C.D., Brown D.M., Abraham P., et al., PIER Study Group. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145 (2008) 239-248
12. Rothenbuehler S.P., Waeber D., Brinkmann C.K., et al. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 147 (2009) 831-837
13. Boyer D.S., Antoszyk A.N., Awh C.C., et al., MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114 (2007) 246-252